Table 2.

Treatment outcomes for active surveillance patients by progression vs. preference

Treatment outcomes	Patients treated for preference (n=12)	Patients treated for clinical progression (n=17)	Combined (n=29)	p for preference vs. progression
Time to treatment, median (IQR)	2.22 (1.69–3.53) years	3.82 (2.57–7.16) years	2.89 (2.00–4.75) years	0.032
Treatment type	6 nephrectomy (50.0%)	12 nephrectomy (70.6%)	18 nephrectomy (62.1%)	0.44
	6 RFA (50.0%)	5 RFA (29.4%)	11 RFA (37.9%)
Final nephrectomy histology	3 clear-cell RCC (50.0%)	10 clear-cell RCC (83.3%)	13 clear-cell RCC (72.2%)	0.27
	3 papillary type 1 (50.0%)	2 papillary type 1 (16.7%)	5 papillary type 1 (27.8%)
Nephrectomy stage	6 pT1a (100%)	5 pT1a (41.7%)	11 pT1a (61.1%)	0.07
		5 pT1b (41.7%)	5 pT1b (27.8%)
		2 pT3b (16.7%)	2 pT3b (11.1%)
Nephrectomy grade	2 grade 1 (33.3%)	2 grade 1 (16.7%)	4 grade 1 (22.2%)	0.82
	3 grade 2 (50.0%)	6 grade 2 (50.0%)	9 grade 2 (50.0%)
	1 grade 3 (16.7%)	4 grade 3 (33.3%)	5 grade 3 (27.8%)

IQR: interquartile range; RCC: real cell carcinoma; RFA: renal frequency ablation.